{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T02:30:44Z","timestamp":1773455444285,"version":"3.50.1"},"reference-count":28,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003286","name":"Kuwait Foundation for the Advancement of Sciences","doi-asserted-by":"publisher","award":["RA HM-2021-008"],"award-info":[{"award-number":["RA HM-2021-008"]}],"id":[{"id":"10.13039\/501100003286","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Introduction: The immunogenicity of SARS-CoV-2 vaccines in patients with inflammatory bowel disease (IBD) on biologic therapies is not well studied. The goal of this study was to measure the serological response to BNT162b2 and ChAdOx1 nCoV-19 vaccines in patients with IBD receiving different biologic therapies. Methods: We performed a multi-center prospective study between 1 August 2021 and 15 September 2021. We measured the seropositivity of SARS-CoV-2 antibodies (SARS-CoV-2 IgG) and neutralizing antibody concentrations in patients with IBD receiving biologic therapies 4\u201310 weeks after their second dose or 3\u20136 weeks after their first dose of BNT162b2 or ChAdOx1 nCoV-19 vaccines. Results: A total of 126 patients were enrolled (mean age, 31 years; 60% male; 71% Crohn\u2019s disease, 29% ulcerative colitis). Of these, 92 patients were vaccinated with the BNT162b2 vaccine (73%) and 34 patients with the ChAdOx1 nCoV-19 vaccine (27%). In patients being treated with infliximab and adalimumab, the proportion of patients who achieved positive anti-SARS-CoV-2 IgG antibody levels after receiving two doses of the vaccine were 44 out of 59 patients (74.5%) and 13 out of 16 patients (81.2%), respectively. In contrast, of those receiving ustekinumab and vedolizumab, the proportion of patients who achieved positive anti-SARS-CoV-2 IgG antibody levels after receiving two doses of the vaccine were 100% and 92.8%, respectively. In patients receiving infliximab and adalimumab, the proportion of patients who had positive anti-SARS-CoV-2 neutralizing antibody levels after two-dose vaccination was 40 out of 59 patients (67.7%) and 14 out 16 patients (87.5%), respectively. On the other hand, the proportion of patients who had positive anti-SARS-CoV-2 neutralizing antibody levels were 12 out of 13 patients (92.3%) and 13 out of 14 patients (92.8%) in patients receiving ustekinumab and vedolizumab, respectively. Conclusions: The majority of patients with IBD who were on infliximab, adalimumab, and vedolizumab seroconverted after two doses of SARS-CoV-2 vaccination. All patients on ustekinumab seroconverted after two doses of SARS-CoV-2 vaccine. The BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines are both likely to be effective after two doses in patients with IBD on biologics. Larger follow-up studies are needed to evaluate if decay of antibodies occurs over time.<\/jats:p>","DOI":"10.3390\/vaccines9121471","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T01:29:33Z","timestamp":1639358973000},"page":"1471","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2084-3956","authenticated-orcid":false,"given":"Mohammad","family":"Shehab","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Mubarak Alkabeer University Hospital, Kuwait University, Aljabreyah 47060, Kuwait"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatema","family":"Alrashed","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, Health Sciences Center (HSC), Kuwait University, Jabriya 13110, Kuwait"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Alfadhli","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Mubarak Alkabeer University Hospital, Kuwait University, Aljabreyah 47060, Kuwait"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khazna","family":"Alotaibi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Mubarak Alkabeer University Hospital, Kuwait University, Aljabreyah 47060, Kuwait"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Alsahli","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Mubarak Alkabeer University Hospital, Kuwait University, Aljabreyah 47060, Kuwait"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussain","family":"Mohammad","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Mubarak Alkabeer University Hospital, Kuwait University, Aljabreyah 47060, Kuwait"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preethi","family":"Cherian","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Dasman Diabetes Institute (DDI), Dasman 15462, Kuwait"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Al-Khairi","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Dasman Diabetes Institute (DDI), Dasman 15462, Kuwait"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4574-5343","authenticated-orcid":false,"given":"Thangavel","family":"Alphonse Thanaraj","sequence":"additional","affiliation":[{"name":"Department of Genetics and Bioinformatics, Dasman Diabetes Institute (DDI), Dasman 15462, Kuwait"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arshad","family":"Channanath","sequence":"additional","affiliation":[{"name":"Department of Genetics and Bioinformatics, Dasman Diabetes Institute (DDI), Dasman 15462, Kuwait"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6623-3374","authenticated-orcid":false,"given":"Hamad","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Genetics and Bioinformatics, Dasman Diabetes Institute (DDI), Dasman 15462, Kuwait"},{"name":"Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, Health Sciences Center (HSC), Kuwait University, Jabriya 13110, Kuwait"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8357-1252","authenticated-orcid":false,"given":"Mohamed","family":"Abu-Farha","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Dasman Diabetes Institute (DDI), Dasman 15462, Kuwait"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jehad","family":"Abubaker","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Dasman Diabetes Institute (DDI), Dasman 15462, Kuwait"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5409-3829","authenticated-orcid":false,"given":"Fahd","family":"Al-Mulla","sequence":"additional","affiliation":[{"name":"Department of Genetics and Bioinformatics, Dasman Diabetes Institute (DDI), Dasman 15462, Kuwait"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,13]]},"reference":[{"key":"ref_1","unstructured":"(2021, October 10). CDC. Human Coronavirus Types. COVID-19, Available online: https:\/\/www.cdc.gov\/coronavirus\/types.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"taab083","DOI":"10.1093\/jtm\/taab083","article-title":"Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses","volume":"28","author":"Chemaitelly","year":"2021","journal-title":"J. Travel Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1053\/j.gastro.2013.10.047","article-title":"American gastroenterological association institute guideline on the use of thiopurines, methotrexate, and anti-TNF-\u03b1 biologic drugs for the induction and maintenance of remission in inflammatory Crohn\u2019s disease","volume":"145","author":"Terdiman","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with crohn\u2019s disease: More than 5 years of follow-up in the TREAT registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e000774","DOI":"10.1136\/bmjgast-2021-000774","article-title":"The Impact of Medical Therapies for Inflammatory Bowel Disease on the Severity of COVID-19: A Systematic Review and Meta-analysis","volume":"8","author":"Alrashed","year":"2021","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1053\/j.gastro.2020.04.002","article-title":"Management of Patients With Crohn\u2019s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting","volume":"159","author":"Rubin","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"12","author":"Altman","year":"2014","journal-title":"Int. J. Surg."},{"key":"ref_12","unstructured":"World Health Organization (2004). ICD-10: International Statistical Classification of Diseases and Related Health Problems: Tenth Revision, World Health Organization. [2nd ed.]."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.7326\/M21-1757","article-title":"Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2","volume":"174","author":"Deepak","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Melmed, G.Y., Botwin, G.J., Sobhani, K., Li, D., Prostko, J., Figueiredo, J., Cheng, S., and Braun, J. (2021). Antibody Responses After SARS-CoV-2 mRNA Vaccination in in Adults With Inflammatory Bowel Disease. Ann Intern. Med., 2\u20134.","DOI":"10.7326\/M21-2483"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2021.05.044","article-title":"Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications","volume":"161","author":"Khan","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2021.04.025","article-title":"Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies","volume":"161","author":"Wong","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1053\/j.gastro.2021.06.076","article-title":"BNT162b2 Messenger RNA COVID-19 Vaccine Effectiveness in Patients With Inflammatory Bowel Disease: Preliminary Real-World Data During Mass Vaccination Campaign","volume":"161","author":"Banon","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"327","DOI":"10.5937\/jomb0-32373","article-title":"Anti-spike s1 iga, anti-spike trimeric igg, and anti-spike rbd igg response after bnt162b2 covid-19 mrna vaccination in healthcare workers","volume":"40","author":"Salvagno","year":"2021","journal-title":"J. Med. Biochem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102125","DOI":"10.1016\/j.scr.2020.102125","article-title":"Neutralizing antibodies targeting SARS-CoV-2 spike protein","volume":"50","author":"Xiaojie","year":"2021","journal-title":"Stem Cell Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1136\/gutjnl-2021-324789","article-title":"Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD","volume":"70","author":"Kennedy","year":"2021","journal-title":"Gut"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"9300","DOI":"10.3748\/wjg.v22.i42.9300","article-title":"Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases","volume":"22","author":"Billmeier","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/gutjnl-2014-307127","article-title":"Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: Randomised controlled trial results","volume":"64","author":"Wyant","year":"2015","journal-title":"Gut"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/14712598.2019.1561850","article-title":"Anti-interleukin-12 and anti-interleukin-23 agents in Crohn\u2019s disease","volume":"19","author":"Macaluso","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/gutjnl-2020-324000","article-title":"SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: Recommendations from an international consensus meeting","volume":"70","author":"Siegel","year":"2021","journal-title":"Gut"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Lin, S., Kennedy, N., Saifuddin, A., Sandoval, D.M., Reynolds, C., Seoane, R.C., Kottoor, S., Pieper, F., Lin, K.-M., and Butler, D.K. Covid-19 Vaccine-Induced Antibodies Are Attenuated and Decay Rapidly in Infliximab Treated Patients. Research Square, 2021.","DOI":"10.21203\/rs.3.rs-755879\/v1"},{"key":"ref_27","unstructured":"(2021, October 05). FDA\/CEDR Resources Page. FDA Authorizes Booster Dose of Pfizer-BioNTech COVID-19 Vaccine for Certain Populations. Food and Drug Administration, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-authorizes-booster-dose-pfizer-biontech-covid-19-vaccine-certain-populations."},{"key":"ref_28","unstructured":"Alexander, J.L., Moran, G., Gaya, D.R., Raine, T., Hart, A., Kennedy, N.A., Lindsay, J.O., Macdonald, J., Segal, J.P., and Sebastian, S. (2021, October 10). BSG Inflammatory Bowel Disease Section and Clinical Research Group Position Statement on SARS-CoV2 Vaccination|The British Society of Gastroenterology. Available online: https:\/\/www.bsg.org.uk\/covid-19-advice\/british-society-of-gastroenterology-inflammatory-bowel-disease-section-and-ibd-clinical-research-group-position-statement-on-sars-cov2-vaccination\/."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/12\/1471\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:46:12Z","timestamp":1760168772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/12\/1471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,13]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["vaccines9121471"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9121471","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.10.31.21265718","asserted-by":"object"}]},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,13]]}}}